Leading pharmaceutical companies are pushing back against U.S. President Donald Trump’s proposed global drug tariffs, warning that an abrupt implementation could disrupt medical supply chains, escalate compliance costs, and limit…
In a major advancement for rare disease treatment and regulatory medicine, the U.S. Food and Drug Administration (FDA) has approved the expanded use of Amgen’s Uplizna (inebilizumab) as the first…
In a significant development within the pharmaceutical regulatory landscape, GlaxoSmithKline (GSK) and Pfizer have agreed to end a high-profile legal dispute involving patent infringement claims tied to their respiratory syncytial…
The European Medicines Agency (EMA) has initiated a review of GlaxoSmithKline’s (GSK.L) request to expand the use of its asthma drug Nucala (mepolizumab) as an additional treatment for chronic obstructive…
On World Tuberculosis (TB) Day, the World Health Organization (WHO) has issued a dire warning, emphasizing the urgent need for increased investment in TB care. The organization lamented that severe…
Sanofi (SASY.PA) has entered into an agreement to acquire Dren Bio’s immunology unit, securing rights to its autoimmune disease treatment, DR-0201.
As part of the deal, the French pharmaceutical giant will…
Eli Lilly (LLY.N) has officially launched its blockbuster diabetes and weight-loss drug, Mounjaro, in India after securing approval from the country’s drug regulator. The move presents a significant market opportunity…
Priscilla Chan, co-founder of the Chan Zuckerberg Initiative (CZI), envisions a future where artificial intelligence (AI) transforms medical research, enabling the early detection and prevention of diseases within the next…
Generative artificial intelligence (GenAI) is no longer a distant innovation but a transformative force reshaping the healthcare sector. With promising early outcomes, healthcare organizations are rapidly scaling their investments in…